BioInvent International
37.15
SEK
+0.68 %
Less than 1K followers
BINV
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
+0.68%
+26.79%
+46.26%
-3.51%
-15.38%
+7.99%
-15.28%
+4.6%
-96.1%
BioInvent International is a biotechnology company focused on the development of innovative antibody therapies for cancer treatment. The company researches new treatments that can improve patient outcomes and quality of life. The company operates globally with a presence in international markets. BioInvent International was founded in 1983 and is headquartered in Lund.
Read moreMarket cap
2.44B SEK
Turnover
119.52K SEK
Revenue
44.69M
EBIT %
-1,054.06 %
P/E
-
Dividend yield-%
-
Financial calendar
26/8
2025
Interim report Q2'25
29/10
2025
Interim report Q3'25
All
Webcasts
Press releases
ShowingAll content types
XOMA Royalty förvärvar mezagitamab royalty- och milstolpsrättigheter av BioInvent International för upp till 30 miljoner USD
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD 30 Million
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools